such as DM and periodontal disease (Keating, Plutzky, & El-Osta, 2016; Larsson, Castilho, & Giannobile, 2015; Ling & Groop, 2009; Martins et al., 2016) , microRNAs (miRs), might acting as epigenetic regulators, draw an attention. miRs are small, non-coding RNAs that can suppress expression of a variety of genes thereby orchestrating a number of processes, such as host cell immune responses (Moffatt & Lamont, 2011) including antibacterial (Li et al., 2016) and anti-inflammatory as well as antioxidative (Hulsmans, De Keyzer, & Holvoet, 2011) . It is noteworthy that circulating miRs (in serum, saliva and other body fluids), due to their stability and distinctive function, have an advantage of being biomarkers compared with other biomarkers such as proteins or bacterial products (Kim et al., 2015) . It is noteworthy that salivary miRs have been evaluated as diagnostic biomarkers for oral squamous cell carcinomas (Zahran, Ghalwash, Shaker, Al-Johani, & Scully, 2015) . On the other side, as miR activity and function could be modified in patients by pharmacological modulation, they are considered to be attractive therapeutic targets in a variety of diseases, among them DM micro-and macrovascular complications (van Rooij, Purcell, & Levin, 2012) . In this research, we focused on the two immunomodulatory miRs, miR-146a and miR-155, which are co-induced in many cell types responding to microbial lipopolysaccharide, facilitating a negative feedback control of NFkB target genes which encode various mediators of inflammation (Ma, Becker Buscaglia, Barker, & Li, 2011; Taganov, Boldin, Chang, & Baltimore, 2006) and involved in oxidative stress by targeting superoxide dismutase (SOD) (Ji et al., 2013) . Noteworthy, periodontitis patients had higher gingival tissue levels of miR-146a accompanied with the reduced levels of inflammatory cytokines than healthy (Motedayyen, Ghotloo, Saffari, Sattari, & Amid, 2015) . We aimed to quantify expression levels of miR-146 and miR-155 in gingival crevicular fluid obtained from non-diabetic and type 2 diabetic periodontitis patients, at baseline and after non-surgical periodontal treatment to examine their association with periodontal status as well as oxidative stress.
| MATERIALANDME THODS

| Studypopulation
Ninety-six subjects (44 males and 52 females, mean age 44.13 ± 12.46), chosen among individuals with periodontitis (n = 48) and periodontally healthy controls (n = 48) undergoing dental examination, were included in this study. The study details were fully explained to the participants, and the written consents were obtained. The study protocol was approved by the Ethical Research Committee of the School of Dental Medicine, University of Belgrade, Serbia (ethics approval № 36/3).
Subjects were allocated in one of the four groups: CP (24 healthy individuals with chronic periodontitis), CPDM (24 patients with chronic periodontitis in association with DM type 2), PH (24 healthy individuals with clinically healthy periodontium) or PHDM group (24 patients with clinically healthy periodontium in association with DM type 2). The sample size calculation was based on data of the previous studies on acute increase in miR-146a in inflamed periodontal tissue (Xie, Shu, Jiang, Liu, & Zhang, 2011) and DM (Rong et al., 2013) . A total number of 96 participants (24 subjects per group) were needed to demonstrate a large difference (effect size-0.4) in gingival crevicular fluid (GCF) levels of miRs between groups with the test power of 90% and the alpha probability of .05.
Calculation was made using ANOVA for independent groups (statistical software package GPower 3.1).
Inclusion criteria for subjects in PH group and CP group were as follows: ≥18 years of age, self-reported good general health, ≥20 erupted teeth excluding third molars, no periodontal treatment in previous 6 months. Periodontally healthy participants that were included in this study had to have no gingival inflammation (gingival index, GI = 0) and probing depth ≤3 mm in every site (Himani, Prabhuji, & Karthikeyan, 2014) . Participants with moderate or severe chronic periodontitis had to have at least four sites with a probing pocket depth (PPD) of ≥4 mm along with the presence of attachment loss of ≥3 mm and GI ≥ 1 (Armitage, 2004) .
The enrolled diabetic patients were diagnosed with type 2 DM for at least 2 years and did not suffer with any additional systematic diseases. Only well-controlled diabetic patients who had exhibited HbA1c levels of <8% were eligible for the study (Ribeiro et al., 2011) .
Exclusion criteria for all participants were as follows: (i) smoking; (ii) presence of any other systemic diseases; (iii) the use of immunosuppressants, antibiotics, anti-inflammatory drugs in the last 6 months; (iv) dietary supplementations; (v) pregnancy or lactation. No previous study reported miRs in GCF from patients with periodontitis and DM.
| Clinicaloutcomevariables
Principal findings: Expression levels of miR-146a and miR-155 were significantly increased in GCF of periodontitis patients with/without DM type 2 relative to healthy while decreased after non-surgical periodontal therapy.
Practical implications: Present results imply that miR-146a
and miR-155 in GCF could be potential biomarkers for periodontitis in non-diabetic as well as type 2 diabetic patients. distolingual) was carried out. The following clinical parameters were recorded: (i) PPD-distance between the gingival margin and the bottom of the sulcus/pocket; (ii) clinical attachment level (CAL)-distance between the cemento-enamel junction and the depth at which the probe met resistance; (iii) bleeding on probing (BOP) (Ainamo & Bay, 1975 )-measured 15 s after probing and recorded as presence (1) or absence (0) (iv) gingivitis index (GI) (Loe & Silness, 1963); plaque index (PI) (Silness & Loe, 1964) .
The clinical parameters were recorded by the well-experienced periodontist (NNJ). Intraexaminer calibration was performed twice, before and during the study to ensure intraexaminer con- 
| GCFsampling
| miRexpressionmeasurements
Total RNA was extracted using miRCURY™ RNA Isolation KitsBiofluids (Exiqon A/S, Vedbaek, Denmark), according to the manufacturer's instructions. and specific assays: hsa-miR-146a (ID:000468); hsa-miR-155(ID: 002623); and RNU6B (ID:001093), using standard temperature conditions. All reactions were run on Real Time PCR 7500 (Applied Biosystems). Expression levels of miRs were presented in relative units, and normalized to RNU6B, as the endogenous control.
Comparison of RNU6B values between the groups showed no significant difference (p > .05, Mann-Whitney test).
As a calibrator reference (1X sample), the sample with the lowest relative quantity (RQ) value was used, and data were analysed with the 7500 System SDS Software (Applied Biosystems), by comparative ΔΔCt method.
| SODactivitymeasurements
Superoxide dismutase activity (%) in GCF was measured by SOD determination kit (Sigma-Aldrich, USA) according to manufacturer instructions.
| Statisticalanalysis
Results analysis was used with the relative expression of miRs as dependent and periodontitis, age and gender as independent variables. To evaluate accuracy of the miR-146a and miR-155 in differentiating healthy from moderate to severe periodontitis patients, the receiver operating characteristic (ROC) curves were constructed by calculating the area under the curve (AUC) and identifying cut-off points to estimate the highest sensitivity and specificity as assessed by Youden's index.
Calculations were performed using software package (SPSS 18.0, IBM Statistics, USA), and differences were considered significant at p˂.05.
| RE SULTS
| Characteristicsofthesubjects
The mean age of participants was significantly higher in the periodontitis groups, both in non-diabetic and in type 2 diabetic, in comparison with the groups of periodontally healthy participants.
There were no significant differences between gender distribution within and between the groups. Patients showed moderate overweight with no differences in mean BMI between the groups observed ( 
| miR-146aandmiR-155expressionlevelsin
GCFofnon-diabeticandtype2diabeticsubjects miR-146a levels were higher in type 2 diabetic compared to nondiabetic periodontally healthy patients. In CP and CPDM patients, miR-146a and miR-155 levels were significantly enhanced before non-surgical therapy while the levels decreased after the therapy to the levels comparable to periodontally healthy patients (Figure 1 ). Multiple linear regression analyses revealed that periodontitis contributed significantly to the GCF expression levels of miR-146a and miR-155, when adjusting for age and gender (Table 2 ). There were no significant correlations between BMI values and investigated miRs (Supplementary material). The accuracy of miR-146a and miR-155 as GCF biomarkers of periodontitis is illustrated with ROC curves (Figure 2 ) and their respective values (Table 3 ). The ROC curves for both miRs in non-diabetic and type 2 diabetic patients showed a high accuracy for CP because AUC ≥ 0.9. miR-146a showed the best performance with a sensitivity of 100%, a specificity of 96%, at a cut-off point of 4.11 au (arbitrary units) in non-diabetic CP patients. In DM type 2 patients, miR-155 showed better performance compared to miR146a with a sensitivity of 92%, a specificity of 100% at cut-off point of 3.56 au (Table 3) . miR-146a showed strong positive correlation with PPD in both non-diabetic and type 2 diabetic periodontitis patients (Spearman r = .676 and r = .641, respectively, p < .01).
Also, miR-155 showed significant positive correlation with PPD in the group of non-diabetic and type 2 diabetic periodontitis patients (Spearman r = .623 and r = .645, respectively, p < .01).
| SODactivity
Activity of major antioxidant enzyme, SOD, is significantly enhanced in CP and CPDM patients' baseline and decreased 6 weeks after nonsurgical therapy to the levels comparable to periodontally healthy 
| Insilicoanalysis
We used ComiR, a web-based software for the combinatorial prediction of mutual targets for miR-146a and miR-155 (Coronnello & Benos, 2013). ComiR calculates the probability of mRNAs to be targeted by a set of miRNAs. ComiR results for the two examined miRNAs from our study (expression levels input data) showed that SOD2 mRNA has the high probability to be recognized (equal abundance = 0.924) suggesting that miR-146a and miR-155 in combination may have exceptionally strong probability to silence SOD2 transcription.
| D ISCUSS I ON
Research based on miRs involvement in periodontal disease is in its infancy. This is, to our knowledge, the first study investigating potential of circulatory miRs, obtained in GCF, as biomarkers of periodontal disease. We have quantified miRs expression in GCF because it represents an inflammatory exudate that reflects an ongoing processes in inflamed periodontium more reliably than saliva or serum.
miRs persist in body fluids as circulatory and exosomal (Zhang et al., 2015) and Present results show that in non-diabetic and type 2 diabetic periodontitis patients, miR-146a and miR-155 show significantly higher levels compared with periodontally healthy and that nonsurgical periodontal therapy significantly reduced expression levels of both miRs in GCF reflecting the reduction in periodontal inflammation observed clinically. Considering the higher age of subjects in the periodontitis groups relative to the periodontally healthy subjects, we used multiple regression analyses adjusted for age in order our results to be applicable to younger patients, also.
Levels of both, miR-146a and miR-155, could differentiate between healthy and moderate to severe periodontitis patients with high accuracy based on ROC curves analysis pointing at better performance of miR-146a in non-diabetic, and miR-155 in type 2 diabetic patients. In the previous studies, Motedayyen et al. (2015) showed upregulation of miR-146a in the gingiva of patients with chronic periodontitis while Xie et al. (2011) Namely, the authors found that upon LPS stimulation, miR-146 and miR-155 act in two-tier manner: miR-146 is firstly activated at low LPS doses while miR-155 is gradually induced to full expression and represents limiter of proinflammatory gene expression when the miR-146-dependent anti-inflammatory effect has been breached. To investigate regulatory roles of these two miRs in periodontitis patients, we used in silico analysis (Coronnello & Benos, 2013) . The obtained results showed that these two miRs in combination may have exceptionally strong probability to regulate SOD2 gene expression, suggesting miR-146a and miR-155 action in periodontal disease may involve regulation of oxidative stress. Namely, SOD2 is an mitochondrial antioxidant enzyme but mainly, all three types of SOD act in the same manner, by catalysing neutralization of superoxide anions to oxygen and H 2 O 2 . In the present study, we measured SOD activity which reflects ROS generation and found it to be highly positively correlated with miR-146a and miR-155 expression levels in both, non-diabetic and type 2 diabetic periodontitis patients. Indeed, in in vitro experiments (PC 12 cell line) showed that H 2 O 2 , the product of SOD activity, induced expression of miR-146a (Ji et al., 2013) which then feedback-represses SOD2 gene expression. Moreover, in the F I G U R E 1 Relative expression levels of microRNA-146a (miR-146a) and microRNA-155 (miR-155) in gingival crevicular fluid (GCF) samples. Boxplots represent levels of miR-146a and miR-155 in GCF of periodontal healthy: non-diabetic (PH) and type 2 diabetic (PHDM) as well as in patients with periodontitis: non-diabetic (CP) and type 2 diabetic (CPDM) patients, baseline and 6 weeks after non-surgical therapy. *p < .05 and **p < .01 compared to PH; # p < .05 compared to PHDM patients; ‡p < .01 before versus after non-surgical periodontal therapy present study, reduction of inflammation in periodontal tissues after non-surgical therapy decreases levels of SOD activity as well as miR146a and miR-155 expressions. Very recent study showed that circulatory miR-21, miR-23a and miR-222 regulate expression of SOD2, enzyme described as a cell protector in the diabetic cardiomyopathy (Dubois-Deruy et al. 2017 , Shen et al. 2006 ).
In GCF of type 2 diabetic patients with no signs of periodontal disease, we found higher miR-146a expression levels compared to
The receiver operating characteristic (ROC) curves for differentiating healthy from chronic periodontitis patients using expression levels of microRNA-146a (miR-146a) in non-diabetic (a) and type 2 diabetic (b) patients and of non-diabetic periodontally healthy subjects. In line with this, Rong et al. (2013) found upregulated plasma circulatory levels of miR-146a in DM type 2 patients and suggested that expression of circulating miR-146a could hold predictive value for DM type 2 (Rong et al., 2013) . Moreover, it seems that upregulation of miR-146a in DM exerts a protective effect by downregulating NF-κB's target genes such as TNF alpha thereby reducing inflammation (Bhatt et al., 2016; Ye & Steinle, 2016) . In the present study, periodontitis patients with DM type 2, although with well-controlled glycemia, showed more severe and extensive periodontal inflammation. Usually, such findings were explained by increased inflammatory response to bacteria in DM (Graves, Liu, & Oates, 2007) , but mechanisms are not elucidated.
The present results showing no difference in miR-146a expression in CPDM compared to CP suggest complex engagement of miR-146a in immunomodulation depending on a different physiopathological context (periodontitis and/or DM) and point at importance of miR-155 co-involvement in CPDM. Schulte et al. (2013) showed that as a consequence of differential regulation, upregulated miR-146 under the invasion of bacteria may augment the initial LPS threshold required for miR-155 activation. In such context, it seems possible that upregulated miR-146a in type 2 diabetic patients observed presently, when exposed to periodontal pathogens may postpone the anti-inflammatory effect of miR-155 resulting in augmented inflammation in periodontal tissues. On the other hand, there is a proposition that circulatory miRs released in the body fluids could be taken up by neighbour or distant endothelial or immune cells acting as local or systemic communication tools (Ling & Groop, 2009; Zhang et al., 2015) . Under the diabetic condition, hyperglycaemia or inflammation exert epigenetic alterations in host tissues which in turn change circulating miRs profiles and disseminate incorrect epigenetic signature to neighbour or distant cells, a phenomenon defined as epigenetic damage transmission (Prattichizzo et al., 2016) .
Therefore, it seems reasonable to assume that alteration of miR146a expression in GCF of type 2 diabetic patients could affect the inflammatory milieu of neighbour tissues resulting in more severe periodontal damage in DM patients.
Limitation of the present study was that we did not evaluate serum miR-146a levels to investigate whether GCF miR-146a levels may reflect its systemic levels in type 2 diabetic patients. However, based on previous (Rong et al., 2013 and Baldeón et al. 2014 ) as well as on our present study, it may be possible to resume that obesity and/or dyslipidaemia status, the stage of type 2 diabetes as well as an associate inflammatory events affect circulatory miR-146a expression and therefore further investigation is needed to qualify miR-146a as reliable biomarker of type 2 DM.
It is noteworthy that recent studies showed that host immune reactions against periodontal bacteria could promote the development of atherosclerosis associated with diabetic vascular disease (Aarabi, Eberhard, Reissmann, Heydecke, & Seedorf, 2015; Reyes, Herrera, Kozarov, Roldan, & Progulske-Fox, 2013) . The underlying mechanism proposed include activation of T helper 17-inducing pathways involved in atherosclerotic plaque formation (Cai, Kobayashi, HashizumeTakizawa, & Kurita-Ochiai, 2014) . Having in mind that periodontal bacteria may activate T helper 17 by upregulating miR-155 (Du et al., 2014) , it seems reasonable to speculate that downregulation of miR-155, achieved by non-surgical periodontal therapy as shown presently, may be beneficial in reducing risk for vascular disease development.
In conclusion, the present study is the first to provide evidence that GCF expression levels of both miR-146a and miR-155 could be considered as potential biomarkers for periodontal disease in nondiabetic and type 2 diabetic periodontitis patients. Furthermore, we found the association of these gene regulators with oxidative stress mechanisms. Further elucidation of the detailed miRNA-146a and miRNA-155 mechanisms involved in the periodontal inflammation especially in the setting of DM could expand the knowledge of the TA B L E 3 Accuracy of miR-146a and miR-155 as biomarkers of chronic periodontitis in non-diabetic and type 2 diabetic patients F I G U R E 3 The activity of superoxide dismutase (SOD) in gingival crevicular fluid (GCF) samples. Boxplots represent the SOD activity in GCF of periodontal healthy: non-diabetic (PH) and type 2 diabetic (PHDM) as well as in patients with periodontitis: non-diabetic (CP) and type 2 diabetic (CPDM) patients, baseline and after non-surgical therapy. **p < .01 compared to PH; # p < .01 compared to PHDM patients; ‡ p < .01 baseline versus after nonsurgical periodontal therapy pathogenesis of periodontal disease and enable development of improved treatment strategies.
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